Fig. 5
From: Anxiety-like behavior and anxiolytic treatment in the Rett syndrome natural history study

Frequency of anxiolytic use reported in medication logs by MECP2 pathogenic variant. MECP2 variant percent in parentheses indicates overall frequency of the variant in the entire study population. †Severe variant = R106W, R168X, R255X, R270X, early truncations, large deletions, and splice site. First iteration = subjects enrolled 2006–2015; second iteration = subjects enrolled 2015–2019